All In Biotech

NDA 210296 · Banner Life Sciences

Bafiertam

Monomethyl Fumarate · Oral

Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Apr 28, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

80

4 Phase 3, 14 recruiting

FAERS reports

935

127 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 16, 2026.

BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: The mechanism by which monomethyl fumarate (MMF) exerts its therapeutic effect in multiple sclerosis is unknown. MMF has been shown to activate the Nuclear factor (erythroid-derived 2) like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BAFIERTAM · MONOMETHYL FUMARATE 95MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Monomethyl" as an intervention, any sponsor and status, largest first.

All 80 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • flushing350
  • pruritus110
  • product dose omission issue83
  • nausea76
  • abdominal discomfort65
  • erythema65
  • abdominal pain upper51
  • fatigue47
  • diarrhoea46
  • rash44
  • dizziness43
  • paraesthesia43

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
20201
202173
2022227
2023166
2024318
2025110
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bafiertam (Monomethyl Fumarate)

2024 spending

$8.2M

Beneficiaries

172

999 claims

Per beneficiary

$47,919

$54.38 per unit

View as table
YearSpending
2020$0
2021$767,710
2022$3,109,005
2023$4,951,676
2024$8,241,991

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 484 on PubMed

Sponsor: Banner Life Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.